GW Pharma (GWPH) Stock Could Surge on Earnings Today

GW Pharma (GWPH) has the distinction of having the first two cannabis-derived prescription drugs that were approved by the FDA: Epidiolex and Sativex.  …

GW Pharmaceuticals (GWPH) Stock Finds a Fan in J.P Morgan

J.P Morgan analyst Cory Kasimov initiates coverage for medical cannabis company GW Pharmaceuticals (GWPH), calling it a “clear leader” in the field of cannabinoid …

Cantor Weighs in on GW Pharmaceuticals (GWPH) Stock Following DEA Rescheduling

This morning, GW Pharmaceuticals (GWPH) announced that EPIDIOLEX (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S.

GW Pharma (GWPH) Stock Gets Price-Target Hike Following FDA Approval

There’s a new FDA-approved cannabis-based medicine on the scene. Today, the U.

GW Pharmaceuticals (GWPH): Cowen Counts on ‘Wide Adoption’ for Epidiolex in Refractory Epilepsies

Cowen’s Phil Nadeau joins the bullish conversation buzzing about GWPh’s cannabis-based epilepsy drug after a unanimous nod from the FDA AdCom panel.

GW Pharmaceuticals (GWPH): Epidiolex Will Be Approved Much Before the PDUFA Date, Bets Cantor

Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.

GW Pharmaceuticals (GWPH) Lead Drug’s Green Light Just Around the Corner? Cowen Joins the Conversation

On back of yesterday’s positive briefing documents, Cowen’s Phil Nadeau roots for FDA approval.

Why GW Pharmaceuticals (GWPH) Stock Is Posting Strong Gains Today

GW Pharmaceuticals (NASDAQ:GWPH) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 11% upturn. …

Philip Hempleman Hits the Ground Running in Helios and Matheson Analytics Inc (HMNY), GW Pharmaceuticals PLC- ADR (GWPH)

The hedge fund firm founder is stepping into tech stock HMNY and biopharma stock GWPH; here’s how these Q4 moves measure up against the word on the Street.

Cowen Remains Bullish on GW Pharmaceuticals PLC- ADR (GWPH) Despite Unsuccessful Phase 2 Trial in Focal Seizures

If you’ve been waiting patiently on the sidelines for a pullback in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), it’s here. The drug maker’s shares …